Skip to content
Screener

Bioventus BVS Q3 2025 earnings

Reported November 4, 2025 · Before market open

Revenue$138.7MMiss by $17.1M
EPS$0.15Miss by $0.07
Revenue estimate$155.7M
EPS estimate$0.22

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$149.5M
EPS estimate$0.17

Financials

Q3 2025

Income statement

See full
Revenue$138.7M-0.2%
Gross profit$94.2M+0.7%
Operating income$11.3M+209%
Net income$3.2M+161%
EPS (diluted)$0.05+163%

Balance sheet

See full
Cash & equivalents$42.2M-2.1%
Total debt$341.2M-15.8%
Total equity$166.1M+11.7%
Total assets$701.6M-8.8%

Cash flow

See full
Operating cash flow$30.1M+192%
CapEx$473.0K+639%
Free cash flow$29.6M+189%

Valuation & ratios

Valuation

as of 09/27/25
See full
Market cap$447.51M-41.5%
Enterprise value$746.51M-33.8%
P/E59×—
P/S0.8×-0.6×

Profitability

See full
Gross margin67.8%+0.8pp
Net margin1.3%+0.7pp
FCF margin9.5%+4.3pp

Returns & leverage

See full
Return on equity4.8%+2.6pp
Debt / equity2.1×-0.7×
Current ratio1.7×+0.3×

Segments

By product

See full
Pain Treatments$67.2M+6.4%
Surgical Solutions$50.2M+9.3%
Restorative Therapies$21.3M-28.8%

By segment

See full
U.S. Segment$123.3M+0.3%
International Segment$15.3M-4.5%

FAQ

When did Bioventus report Q3 2025 earnings?
Bioventus (BVS) reported Q3 2025 earnings on November 4, 2025 before market open.
What were Bioventus's Q3 2025 revenue and EPS?
Bioventus reported revenue of $138.7M and eps of $0.15 for Q3 2025.
Did Bioventus beat estimates in Q3 2025?
Revenue missed the consensus estimate of $155.7M by $17.1M. EPS missed the consensus estimate of $0.21 by $0.07.
How did Bioventus's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 0.2% from $139.0M a year earlier and eps grew 150.0% from $0.06.
Where can I find Bioventus's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001665988-25-000025) and the 10-Q periodic report (0001665988-25-000026) directly on SEC EDGAR. The filing index links above go to sec.gov.